Cost-effectiveness of pharmaceutical care on patients undergoing maintenance hemodialysis–a multicenter randomized controlled study

Uday Venkat Mateti, Anantha Naik Nagappa, Ravindra Prabhu Attur, Shankar Prasad Nagaraju, Dharshan Rangaswamy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: The aim of the study is to assess the cost-effectiveness of pharmaceutical care versus usual care on the treatment costs in patients undergoing maintenance hemodialysis (HD) in the outpatient HD centers of academic, government, and corporate hospitals. Methods: An open-labeled randomized controlled study was registered under clinical trial registry of India (Ref. no. CTRI/2014/004900). The study was conducted for a period of 12-month follow-up in patients undergoing maintenance HD. The patients were randomized into Usual Care (UC) group and Pharmaceutical Care (PC) group by the block design method. The UC group received the usual care provided by the hospital staff like physicians, nurses, and technicians whereas, the PC group received the usual care along with the pharmaceutical care delivered by a qualified registered pharmacist. The patient perspective ‘out-of-pocket expenditures’ was considered for calculating the annual cost incurred for the treatment of HD patients. Results: Out of 153 patients, academic hospital (n = 83), government hospital (n = 18), and corporate hospital (n = 52). The incremental cost-effectiveness ratio for academic, government, and corporate hospitals HD patients of PC group compared with UC group were 86,230 Indian Rupee (INR)/Quality-adjusted life year (QALY), 231,016.66 INR/QALY, and 87,430 INR/QALY, respectively. Our study results revealed that PC group was costlier and more effective compared to the UC group. Conclusions: It depends upon the policymakers and regulators to take the decision, if they believe that the extra cost is worth the extra QALY.

Original languageEnglish
Pages (from-to)621-626
Number of pages6
JournalPostgraduate Medicine
Volume130
Issue number7
DOIs
Publication statusPublished - 03-10-2018

Fingerprint

Pharmaceutical Services
Cost-Benefit Analysis
Quality-Adjusted Life Years
Maintenance
Renal Dialysis
Health Care Costs
Health Expenditures
Pharmacists
Registries
India
Patient Care
Outpatients
Nurses
Clinical Trials
Physicians
Costs and Cost Analysis

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{6f23f63687ca4a879a2dee2c76d39e9d,
title = "Cost-effectiveness of pharmaceutical care on patients undergoing maintenance hemodialysis–a multicenter randomized controlled study",
abstract = "Objectives: The aim of the study is to assess the cost-effectiveness of pharmaceutical care versus usual care on the treatment costs in patients undergoing maintenance hemodialysis (HD) in the outpatient HD centers of academic, government, and corporate hospitals. Methods: An open-labeled randomized controlled study was registered under clinical trial registry of India (Ref. no. CTRI/2014/004900). The study was conducted for a period of 12-month follow-up in patients undergoing maintenance HD. The patients were randomized into Usual Care (UC) group and Pharmaceutical Care (PC) group by the block design method. The UC group received the usual care provided by the hospital staff like physicians, nurses, and technicians whereas, the PC group received the usual care along with the pharmaceutical care delivered by a qualified registered pharmacist. The patient perspective ‘out-of-pocket expenditures’ was considered for calculating the annual cost incurred for the treatment of HD patients. Results: Out of 153 patients, academic hospital (n = 83), government hospital (n = 18), and corporate hospital (n = 52). The incremental cost-effectiveness ratio for academic, government, and corporate hospitals HD patients of PC group compared with UC group were 86,230 Indian Rupee (INR)/Quality-adjusted life year (QALY), 231,016.66 INR/QALY, and 87,430 INR/QALY, respectively. Our study results revealed that PC group was costlier and more effective compared to the UC group. Conclusions: It depends upon the policymakers and regulators to take the decision, if they believe that the extra cost is worth the extra QALY.",
author = "Mateti, {Uday Venkat} and Nagappa, {Anantha Naik} and Attur, {Ravindra Prabhu} and Nagaraju, {Shankar Prasad} and Dharshan Rangaswamy",
year = "2018",
month = "10",
day = "3",
doi = "10.1080/00325481.2018.1504595",
language = "English",
volume = "130",
pages = "621--626",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "7",

}

Cost-effectiveness of pharmaceutical care on patients undergoing maintenance hemodialysis–a multicenter randomized controlled study. / Mateti, Uday Venkat; Nagappa, Anantha Naik; Attur, Ravindra Prabhu; Nagaraju, Shankar Prasad; Rangaswamy, Dharshan.

In: Postgraduate Medicine, Vol. 130, No. 7, 03.10.2018, p. 621-626.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cost-effectiveness of pharmaceutical care on patients undergoing maintenance hemodialysis–a multicenter randomized controlled study

AU - Mateti, Uday Venkat

AU - Nagappa, Anantha Naik

AU - Attur, Ravindra Prabhu

AU - Nagaraju, Shankar Prasad

AU - Rangaswamy, Dharshan

PY - 2018/10/3

Y1 - 2018/10/3

N2 - Objectives: The aim of the study is to assess the cost-effectiveness of pharmaceutical care versus usual care on the treatment costs in patients undergoing maintenance hemodialysis (HD) in the outpatient HD centers of academic, government, and corporate hospitals. Methods: An open-labeled randomized controlled study was registered under clinical trial registry of India (Ref. no. CTRI/2014/004900). The study was conducted for a period of 12-month follow-up in patients undergoing maintenance HD. The patients were randomized into Usual Care (UC) group and Pharmaceutical Care (PC) group by the block design method. The UC group received the usual care provided by the hospital staff like physicians, nurses, and technicians whereas, the PC group received the usual care along with the pharmaceutical care delivered by a qualified registered pharmacist. The patient perspective ‘out-of-pocket expenditures’ was considered for calculating the annual cost incurred for the treatment of HD patients. Results: Out of 153 patients, academic hospital (n = 83), government hospital (n = 18), and corporate hospital (n = 52). The incremental cost-effectiveness ratio for academic, government, and corporate hospitals HD patients of PC group compared with UC group were 86,230 Indian Rupee (INR)/Quality-adjusted life year (QALY), 231,016.66 INR/QALY, and 87,430 INR/QALY, respectively. Our study results revealed that PC group was costlier and more effective compared to the UC group. Conclusions: It depends upon the policymakers and regulators to take the decision, if they believe that the extra cost is worth the extra QALY.

AB - Objectives: The aim of the study is to assess the cost-effectiveness of pharmaceutical care versus usual care on the treatment costs in patients undergoing maintenance hemodialysis (HD) in the outpatient HD centers of academic, government, and corporate hospitals. Methods: An open-labeled randomized controlled study was registered under clinical trial registry of India (Ref. no. CTRI/2014/004900). The study was conducted for a period of 12-month follow-up in patients undergoing maintenance HD. The patients were randomized into Usual Care (UC) group and Pharmaceutical Care (PC) group by the block design method. The UC group received the usual care provided by the hospital staff like physicians, nurses, and technicians whereas, the PC group received the usual care along with the pharmaceutical care delivered by a qualified registered pharmacist. The patient perspective ‘out-of-pocket expenditures’ was considered for calculating the annual cost incurred for the treatment of HD patients. Results: Out of 153 patients, academic hospital (n = 83), government hospital (n = 18), and corporate hospital (n = 52). The incremental cost-effectiveness ratio for academic, government, and corporate hospitals HD patients of PC group compared with UC group were 86,230 Indian Rupee (INR)/Quality-adjusted life year (QALY), 231,016.66 INR/QALY, and 87,430 INR/QALY, respectively. Our study results revealed that PC group was costlier and more effective compared to the UC group. Conclusions: It depends upon the policymakers and regulators to take the decision, if they believe that the extra cost is worth the extra QALY.

UR - http://www.scopus.com/inward/record.url?scp=85052084010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052084010&partnerID=8YFLogxK

U2 - 10.1080/00325481.2018.1504595

DO - 10.1080/00325481.2018.1504595

M3 - Article

AN - SCOPUS:85052084010

VL - 130

SP - 621

EP - 626

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 7

ER -